Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
Read now
Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Read now
L. Østergaard, Christian S. Frandsen & S. Madsbad. (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology 9:2, pages 241-265.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Articles from other publishers (11)
Xuechang Wang & Suming Ding. (2021) The biological and pharmacological connections between diabetes and various types of cancer. Pathology - Research and Practice 227, pages 153641.
Crossref
Crossref
Emi Kawakita, Fan Yang, Asako Kumagai, Yuta Takagaki, Munehiro Kitada, Yasuo Yoshitomi, Takayuki Ikeda, Yuka Nakamura, Yasuhito Ishigaki, Keizo Kanasaki & Daisuke Koya. (2021) Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling. Molecular Cancer Research 19:1, pages 61-73.
Crossref
Crossref
Jing Huang, Yuntao Jia, Shusen Sun & Long Meng. (2020) Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Yufang Liu, Xiaomei Zhang, Sanbao Chai, Xin Zhao & Linong Ji. (2019) Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. Journal of Diabetes Research 2019, pages 1-10.
Crossref
Crossref
Jetty A. Overbeek, Marina Bakker, Amber A.W.A. van der Heijden, Myrthe P.P. van Herk-Sukel, Ron M.C. Herings & Giel Nijpels. (2018) Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 34:5, pages e3004.
Crossref
Crossref
Ran Lu, Jin Yang, Rui Wei, Jing Ke, Qing Tian, Fei Yu, Junling Liu, Jingjing Zhang & Tianpei Hong. (2018) Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. PLOS ONE 13:6, pages e0198938.
Crossref
Crossref
Mathieu Boniol, Matteo Franchi, Maria Bota, Agnès Leclercq, Joeri Guillaume, Nancy van Damme, Giovanni Corrao, Philippe Autier & Peter Boyle. (2018) Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies. Diabetes Care 41:2, pages 286-292.
Crossref
Crossref
Sudesna Chatterjee, Melanie J Davies & Kamlesh Khunti. (2018) What have we learnt from “real world” data, observational studies and meta-analyses. Diabetes, Obesity and Metabolism 20, pages 47-58.
Crossref
Crossref
Lotte M. Knapen, Roy G. P. J. de Jong, Johanna H. M. Driessen, Yolande C. Keulemans, Nielka P. van Erp, Marie L. De Bruin, Hubert G. M. Leufkens, Sander Croes & Frank de Vries. (2017) Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Diabetes, Obesity and Metabolism 19:3, pages 401-411.
Crossref
Crossref
Fang Hua, Jiao-Jiao Yu & Zhuo-Wei Hu. (2016) Diabetes and cancer, common threads and missing links. Cancer Letters 374:1, pages 54-61.
Crossref
Crossref
Euan Parnell, Timothy M. Palmer & Stephen J. Yarwood. (2015) The future of EPAC-targeted therapies: agonism versus antagonism. Trends in Pharmacological Sciences 36:4, pages 203-214.
Crossref
Crossref